{"drugs":["Prucalopride Succinate"],"mono":{"0":{"id":"930412-s-0","title":"Generic Names","mono":"Prucalopride Succinate"},"1":{"id":"930412-s-1","title":"Dosing and Indications","sub":[{"id":"930412-s-1-4","title":"Adult Dosing","mono":"<ul><li>Prucalopride succinate has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>Safety and efficacy in men not established; use not recommended<\/li><li><b>Constipation, chronic, In women in whom laxatives fail to provide adequate relief:<\/b> 2 mg ORALLY once daily (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"930412-s-1-5","title":"Pediatric Dosing","mono":"Not for use in pediatric patients as efficacy compared with placebo was not established "},{"id":"930412-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Elderly (over 65 years):<\/b> Initial, 1 mg orally once daily; then 2 mg orally once daily if needed<\/li><li><b>Renal impairment, mild to moderate:<\/b> No dosage adjustment necessary<\/li><li><b>Renal impairment, severe (GFR less than 30 mL\/min\/1.73 m(2)):<\/b> Reduce dosage to 1 mg orally once daily<\/li><li><b>Renal impairment, requiring dialysis:<\/b> Use contraindicated<\/li><li><b>Hepatic impairment, mild to moderate:<\/b> No dosage adjustment necessary<\/li><li><b>Hepatic impairment, severe (Child-Pugh class C):<\/b> Initial, 1 mg orally once daily; may increase to 2 mg orally once daily to improve efficacy if 1 mg dose is well tolerated<\/li><\/ul>"},{"id":"930412-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Constipation, chronic, In women in whom laxatives fail to provide adequate relief<br\/>"}]},"3":{"id":"930412-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930412-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to prucalopride succinate or any component of the product<\/li><li>renal impairment requiring dialysis<\/li><li>intestinal perforation or obstruction due to structural or functional disorder of gut wall, obstructive ileus, or severe inflammatory conditions of intestinal tract (eg, Crohn disease, ulcerative colitis, toxic megacolon\/megarectum)<\/li><\/ul>"},{"id":"930412-s-3-10","title":"Precautions","mono":"<ul><li>arrhythmias, history<\/li><li>breastfeeding; use not recommended<\/li><li>cardiovascular disease, ischemic<\/li><li>children and adolescents younger than 18 years; use not recommended<\/li><li>concomitant disease, severe and clinically unstable (eg, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS, other endocrine disorders)<\/li><li>galactose intolerance (rare hereditary problems), Lapp lactase deficiency, or glucose-galactose malabsorption; use not recommended<\/li><li>hepatic impairment, severe (Child-Pugh class C); dose adjustment recommended<\/li><li>men; use not recommended<\/li><li>pregnancy; use not recommended; effective contraception should be used during therapy<\/li><li>renal impairment, severe (GFR less than 30 mL\/min\/1.73 m(2)); dose adjustment recommended<\/li><\/ul>"},{"id":"930412-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930412-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"930412-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (approximately 20%), Diarrhea (approximately 20%), Nausea (approximately 20%)<\/li><li><b>Neurologic:<\/b>Headache (approximately 20%)<\/li><\/ul>"},"6":{"id":"930412-s-6","title":"Drug Name Info","sub":{"2":{"id":"930412-s-6-19","title":"Class","mono":"<ul><li>Serotonin Receptor Agonist, 5-HT4<\/li><li>Stimulant, Gastrointestinal<\/li><\/ul>"},"3":{"id":"930412-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930412-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take with or without food <br\/>"}}}